Frontlight ResearchEarly access
Liver and biliary tract cancer trials in Italy
50 of 88 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 18 November 2026. Ask the study team whether a trial fits you.
- Phase 2Taking peopleVisugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure
- Where
- Bologna, Milan, Ravenna, Rome
- Age
- 18 years to 100 years
- People
- 104 worldwide
- Run by
- CatalYm GmbH
See details and how to joinNCT07219459 · EU 2025-520675-86-00 - Phase 2Taking peopleA Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Where
- Milan, Reggio Emilia, Rome
- Age
- 18 years and over
- People
- 111 worldwide
- Run by
- Bayer
See details and how to joinNCT06760819 · EU 2024-517419-62-00 - Phase 1/2Taking peopleA Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
- Where
- Milan, Rome
- Age
- 18 years and over
- People
- 220 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06428409 · EU 2023-508703-21-00 - Phase 2Not yet taking people in ItalyDB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
- Where
- Bergamo, Brescia, Ferrara, Florence, Milan, Modena, Pavia, Verona
- Age
- 18 years and over
- People
- 750 worldwide
- Run by
- DualityBio Inc.
See details and how to joinNCT06953089 · EU 2025-523895-22-00 - Phase 1/2Taking peopleBOLD-100 in Combination With FOLFOX With or Without Bevacizumab for the Treatment of Advanced, Solid Tumours
- Where
- Milan, Naples, Pisa
- Age
- 18 years and over
- People
- 220 worldwide
- Run by
- Bold Therapeutics, Inc.
See details and how to joinNCT04421820 · EU 2024-517500-11-00 - Phase 3Taking peopleEfficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
- Where
- Candiolo, Genoa, Milan, Monserrato, Naples, Padova, Pisa, Rome, Rozzano, Udine, Verona
- Age
- 18 years and over
- People
- 286 worldwide
- Run by
- Jazz Pharmaceuticals
See details and how to joinNCT06282575 · EU 2023-508219-21-00 - Phase 1Taking peopleA Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
- Where
- Milan, Rozzano, Verona
- Age
- 18 years and over
- People
- 158 worldwide
- Run by
- Alnylam Pharmaceuticals
See details and how to joinNCT06600321 · EU 2024-519499-22-00 - Phase 1/2Taking peopleA Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Where
- Candiolo, Milan, Naples, Rome, Rozzano
- Age
- 18 years and over
- People
- 680 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06330064 · EU 2023-509632-26-00 - Phase 1/2Taking peopleA Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
- Where
- Meldola, Milan, Pisa
- Age
- 18 years and over
- People
- 198 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07291076 · EU 2025-523602-33-00 - Phase 2Taking peopleEvaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease
- Where
- Milan
- Age
- 18 years and over
- People
- 90 worldwide
- Run by
- Delcath Systems Inc.
See details and how to joinNCT06875128 · EU 2025-521966-91-00 - Phase 3Taking peoplePhase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
- Where
- Florence, Milan, Naples, Padova, Rome, Rozzano, Tricase
- Age
- 18 years to 99 years
- People
- 620 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06467357 · EU 2023-508057-19-00 - Phase 3Taking peoplePhase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
- Where
- Bologna, Milan, Palermo, Perugia, Pisa, Roma (RM), Rozzano
- Age
- 18 years and over
- People
- 1,220 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06921785 · EU 2024-518210-81-00 - Phase 1/2Not yet taking people in ItalySymbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
- Where
- Ancona, Bologna, Candiolo, Milan, Naples, Rozzano
- Age
- 18 years and over
- People
- 138 worldwide
- Run by
- Pfizer
See details and how to joinNCT07227012 · EU 2025-523525-17-00 - Phase 1/2Taking peopleThe Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Where
- Candiolo, Milan, Naples, Rome, Rozzano
- Age
- 12 years and over
- People
- 300 worldwide
- Run by
- PMV Pharmaceuticals, Inc
See details and how to joinNCT04585750 - Phase 1Taking peopleStudy of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Where
- Ancona, Bologna, Florence, Milan, Naples, Ravenna
- Age
- 18 years and over
- People
- 1,394 worldwide
- Run by
- Exelixis
See details and how to joinNCT05176483 · EU 2023-510061-10-00 - Phase 3Taking peopleA Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
- Where
- Castellana Grotte, Milan, Pisa, Rome, Rozzano
- Age
- 18 years and over
- People
- 1,100 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07221253 · EU 2025-523085-24-00 - Phase 2Taking peopleFecal Microbiota Transplantation to RESCUE patients with unresectable Hcc progressors to first line therapy with AtezolizUmaB and Bevacizumab (RESCUE-HUB)
- Where
- Bologna
- Age
- 18 years and over
- People
- 15
- Run by
- Azienda Ospedaliero-Universitaria Di Bologna IRCCS Istituto Di Ricerca E Di Cura A Carattere Scientifico
See details and how to join2023-510504-45-00 - Phase 2Taking peopleStudy of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- Where
- Milan, Naples
- Age
- 18 years to 130 years
- People
- 454 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05489211 · EU 2023-509436-26-00 - Phase 2Taking peoplePrecision Medicine in Patients With Unresectable CholAngiocarcinoma: RadioEmbolization and Combined Biological Therapy
- Where
- Bergamo, Milan, Naples, Pisa
- Age
- 18 years to 80 years
- People
- 33
- Run by
- Francesco De Cobelli
See details and how to joinNCT06375915 · EU 2024-516498-57-00 - No phaseTaking peopleOrganoid Models of Hepatocellular Carcinoma
- Where
- Roma
- Age
- 18 years and over
- People
- 150
- Run by
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
See details and how to joinNCT06929845 - Phase 2Not yet taking people in ItalyPrevention of venous thromboembolism in cirrhotic patients with hepatocellular carcinoma
- Where
- Padova, Rome
- Age
- 18 years and over
- People
- 70
- Run by
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
See details and how to join2026-526857-33-00 - Phase 1/2Taking peopleA Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
- Where
- Naples, Padova, Roma, Rozzano
- Age
- 18 years and over
- People
- 630 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT06427941 · EU 2025-524136-19-00 - Phase 2/3Taking peopleCisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence
- Where
- Ancona, Bergamo, Bologna, Brescia, Cuneo, Meldola, Milan, Modena, Monza, Padova, Pavia, Pisa, Ravenna, Rome, Turin, Verona
- Age
- 18 years to 75 years
- People
- 300
- Run by
- Gruppo Oncologico del Nord-Ovest
See details and how to joinNCT06037980 - Phase 2Active, not recruitingStudy of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement
- Where
- Bologna, Rozzano, Verona
- Age
- 18 years and over
- People
- 120 worldwide
- Run by
- Taiho Oncology, Inc.
See details and how to joinNCT05727176 · EU 2023-503665-39-00 - Phase 3Taking peopleA Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician’s Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR) altered, Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma (FIRST-308)
- Where
- Ancona, Candiolo, Meldola, Milan, Naples, Pisa, Rozzano, Siena, Verona
- Age
- 18 years and over
- People
- 126 worldwide
- Run by
- Transthera Sciences (Nanjing) Inc.
See details and how to join2023-505660-11-00